Biotech | April 06, 2022
BioFluidica to introduce next-generation biomarker isolation platform
BioFluidica LiquidScan harnesses the power of microfluidics
BioFluidica LiquidScan harnesses the power of microfluidics
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
It also secures US $ 10 million for US launch and commercialization
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated
